- Previous Close
1.4050 - Open
1.4000 - Bid 1.4000 x --
- Ask 1.4100 x --
- Day's Range
1.3100 - 1.8500 - 52 Week Range
0.5600 - 4.9800 - Volume
115,317 - Avg. Volume
49,196 - Market Cap (intraday)
17.564M - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company's lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
www.aptahem.comRecent News: APTA.ST
View MorePerformance Overview: APTA.ST
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APTA.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APTA.ST
View MoreValuation Measures
Market Cap
17.56M
Enterprise Value
13.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-227.16%
Return on Assets (ttm)
-7.83%
Return on Equity (ttm)
-14.34%
Revenue (ttm)
3.77M
Net Income Avi to Common (ttm)
-8.57M
Diluted EPS (ttm)
-0.6900
Balance Sheet and Cash Flow
Total Cash (mrq)
4.13M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.77M